Passion for Science and
Medical Innovation

About us

Schain Research is a consultancy company specialized in health outcomes studies to support drug development. Sweden has a single universal healthcare system where all residents have a unique identification number, enabling comprehensive follow-up of deidentified patient data from birth to death, and even across generations. The possibility to link a broad range of registries, including data on clinical, genetic and socioeconomic factors, enables unique health outcomes studies.
We support studies from start to end; from feasibility assessments to study planning, and all the way to delivery of study reports and publications. We tailor each project to reflect your specific needs and, via our established network of academic experts and partners, we are able to engage individuals with the right expertise across all therapeutic areas and disciplines.

Frida Schain, Ph.D.

CEO and Founder, Schain Research
Dr Schain has a M.Sc. in Molecular Biology from Lund University and a Ph.D. in Medicine, Hematology, from Karolinska Institutet, where she focused on molecular aspects of inflammation and lymphoma pathogenesis. Her broad experience ranges from academic research and early drug discovery to the medical device and pharmaceutical industry. Her pharmaceutical industry experience includes leadership roles in medical affairs, real-world evidence, epidemiology and commercial aspects of drug development. Most recently, she was a Global Director at Janssen, Johnson & Johnson, focusing on evidence generation from a market access and medical affairs perspective. In this role she was also a member of the global real-world evidence leadership team.

 

 

Christina Jones, Ph.D.

Scientific Director and Data Protection Officer
Dr Jones has a Ph.D. in Developmental Biology from Monash University, Australia, and has worked as a postdoctoral researcher at Karolinska Institutet, Sweden, studying human kidney regeneration. Christina has experience in preclinical research, project management, commercialization, academia/industry/clinical partnerships and scientific writing.

 

 

Kelvin Kwok, Ph.D.

Senior Scientist
Dr Kwok studied Biochemistry at Oxford University and did his Ph.D. in Endocrinology at University of Hong Kong. He has also worked as a postdoctoral researcher at Karolinska Institutet focusing on metabolic diseases before joining Schain Research. He is experienced in pre-clinical and clinical research, data analytics and scientific writing.

 

 

Tina Jacob, Ph.D.

Scientist
Dr Jacob holds a Ph.D. from Karolinska Institutet in Stockholm, Sweden. Before joining Schain Research she focused on dermatology, oncology, and diagnostic assays. She is experienced in pre-clinical research, data analytics, ethical applications, project management, and scientific writing.

 

 

Maria Wahlström

Finance and Administration Manager
Maria is an accounting economist with long and broad experience with project-, sales-, marketing- and administration management within several industries and brands.

Collaboration Partners

  • Annica Dominicus M.Sc., Ph.D.
    Senior Statistical Advisor, SDS

     

    Dr Dominicus has a Ph.D. in Mathematical Statistics from Stockholm University, Sweden. She has extensive experience in study design and analyses related to clinical trials and observational studies, both as a biostatistical consultant and as a part of large pharmaceutical research and development organizations.

  • Jonas Mattsson MD, Ph.D.
    Director Allogeneic Transplant Program, Princess Margaret Cancer Center

    Professor Mattsson has over 20 years of experience in cell therapies and allogeneic stem cell transplantation working as a physician and researcher at Karolinska Insitutet. He is currently Director of the Hans Messner Allogeneic Transplant Program, Toronto, Canada.

  • Magnus Björkholm MD, Ph.D.
    Senior Professor of Medicine, Karolinska University Hospital and Karolinska Institutet

    Professor Björkholm´s research is focused on clinical, experimental and epidemiological studies of malignant hematological diseases, with particular expertise in lymphoma, leukemia, myeloma and myeloproliferative neoplasms. He has authored more than 500 peer reviewed papers.

  • Nurgul Batyrbekova M.Sc.
    Statistical Advisor, SDS

    Nurgul is a statistical advisor and Ph.D. student at Karolinska Institutet. Nurgul has a B.Sc majoring in Mathematics, Operational Research, Statistics and Economics from The University of Warwick, UK and a M.Sc. in Biostatistics from Stockholm University. Nurgul has experience in clinical and health economic data analyses for RWE studies.

  • Robert Szulkin M.Sc., Ph.D.
    Senior Statistical Advisor, SDS

    Dr Szulkin has a M.Sc. in Engineering (Physics) from the Royal Institute of Technology, Stockholm, and a Ph.D. in Biostatistics from Karolinska Institutet. Dr Szulkin has 15+ years of experience working on registry studies, including expertise in methods related to observational studies, epidemiology and oncology.